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STUDIES OF GRANULOCYTE FUNCTION (CHEMILUMINESCENCE RESPONSE) 
IN POSTOPERATIVE INFECTION 
Dietrich Inthorn(1)Thomas Szczeponik(1),Dieter 
Mühlbayer(1)»Marianne Jochum(2), Heinz Redl(3) 
Dept. of Surgery,Klinikum Großhadern (1),Dept. 
of Clinical Chemistry(2),Univ. of Munich,Ludwig 
Boltzmann Institute for Experimental Traumato-
logy, Vienna(3) 
INTRODUCTION 
Due to their a b i l i t y to phagocytose soluble and 
solid agents polymorphnuclear granulocytes (PMN) are predo-
minating in the nonspecific defense System. Activation of 
PMN phagocytosis, intracellular k i l l i n g of microorganisms 
and digestion of foreign bodies proceed with increasing 
hexose monophosphate Shunt activity and non-mitochondrial 
oxygen consumption (Becker et a l . 1958, Sbarra and Kar-
novsky 1959). Düring this "respiratory burst" highly reac-
tive oxygen derivates (0^, FLOp^OH, 0
2
, OCT ) are gene-
rated, which are responsible factors for intracellular mi-
crobicidal activity (Babior et a l . 1973) and which can be 
assayed in diluted whole blood by luminol amplified 
chemiluminescence (CL) (Kato et al 1981). We studied the 
CL-response to in vitro-stimulation in whole blood samples 
of surgical patients in comparison to the disease State. 
MATERIAL AND METHODS 
Patients: 7o men, mean age 58,5 years, and 43 women, mean 
age 61.8 years, with manifest infections or at high risk 
for developing infectious complications were prospectively 
studied. They were adjoined daily to a severity group I -
IV according to the c l i n i c a l l y detectable degree of com-
plications: Group I: 60 patients without postoperative 
complications. Group II: 16 patients with slight or mode-
rate infections (wound infections, regionally limited pe-
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r i t o n i t i s , basal pneumonia). Group III: 1o patients with 
severe postoperative infections (locally not limited soft 
tissue infection, 1 - 2 quadrant Peritonitis, extensive 
broncho-pneumonia). Group IV: 27 patients with sepsis (po-
sitive blood culture, ensured infection focus and remote 
organ f a i l u r e ) . Measurement of CL in Diluted Whole Blood: 
The reaction mixture contained 0.1 ml di-luted blood (5o gl 
EDTA blood + 7oo pl phosphate buffered saline Solution 
with 0.1 % glucose), 1.6 ml Veronal buffer (pH 7.2, con-
taining Ca , Mg + 1 % gluqpse and human albumin each) 
and 0.2 ml luminol (7 x 1o~ M in phosphate buffer, pH 
7.4). Following 1o min. incubation at 37 C the reaction 
was started by addition of o.1 ml opsonized (15 min. at 
37 C with pooled normal serum) zymosan Solution (2o mg/-
ml). The CL (counts per min.) was measured at 37 C (Bio-
lumat 95o5, Fa. Berthold, Wildbad, FRG, Apple II e Compu-
ter) and calculated as the CL-integral over 3o min. for 
the whole sample (= total activity, counts per 3o min.). 
Specific activity was calculated from total activity as 
counts per 3o min. and 1o PMN. Data are indicated as mean 
+ SEM. 
RESULTS 
The specific CL activity of human granulocytes in re-
sponse to the in vitro-stimulus zymosan was slightly dimi-
nished by the anesthesiologic-operative trauma (279 + 43 
counts) followed by an increase up to 844 + 83 counts at 
the 3. postoperative day and a decrease to preopera-
tive activity within the next 4 days. The primary reduc-
tion of specific CL activity however was more than compen-
sated by the postoperative leukocytosis so that total CL 
activity increased already in the early postoperative pha-
se reaching its maximum at the 1. day (Fig.1). 
In patients with microbial-infectious complications 
the total CL activity increased according to the c l i n i c a l 
severity of the inflammation. This was due to an enhan-
ced specific CL response as well as to an increase of WBC. 
Interestingly, even slight to moderate bacterial infec-
tions (group II) induced a mean increase of specific CL 
comparable to that of severe infection (group III), where-
as only during sepsis an additional enhancement of the CL 
response per granulocyte was found (Table 1). This beha-
viour is more clearly demonstrable in the follow up of se-
vere infection or sepsis throughout the course of the di-
sease (Fig. 2). Patients dying in the later phase showed a 
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F i g . 1: Total CL-activity (• ), specific CL-activity 
( A A ) and number of leucocytes (. •) in the con-
trol group. 
distinctly higher total and an intensified specific in v i -
tro-excitability to CL already one day before the c l i n i c a l 
manifestation of the fatal complication. In contrast, in 
surviving patients diagnosis of severe infection coincided 
with the maximum of the CL response. Düring the f i r s t days 
of the follwing inflammatory course the slightly decre-
asing CL values in both groups did not show any s i g n i f i -
cant difference. In the later phase, however, a clear dis-
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Table 1: Total and specific CL-activity in group I - IV 
patients (X + SEM) 
CL preop. I II III IV 
Total 13575 34298 51782 62633 118564 
activity +1778 +3o45 +9162 +13135 +2o762 
Specific 433 573 1o71 1o91 15o3 
activity +57,3 +4o,3 +258 +181 +21o 
Fig. 2. Total CL-activity (left) and specific CL-acti-
vity (right) in patients developing sepsis. patients 
dying in the later course, survivers. 
crimination in the CL activity was observed, although both 
groups showed c l i n i c a l l y an equally severe degree of in-
flammation at this Observation period. The specific CL re-
sponse of PMN of surviving patients stayed in the ränge of 
11oo whilst the excitability of the granulocytes in pa-
tients dying later on increased up to two-fold. Depending 
on the significantly higher decline of circulating leuko-
cytes in the latter patients, the total CL activity in 
their blood samples was similar to those shown by survi-
ving subjects at the last day of severe infection or sep-
sis (Fig. 3). Düring the following recovery period the CL 
response to zymosan further decreased gradually to normal 
values due to decline of specific CL activity and leuko-
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Fig. 3. Total CL-activity (left) and specific CL-acti-
vity (right) from dying patients ( ) and survivers 
in the recovery phase ( ). 
Fig. 4: Specific CL-activity in group IV patients: Sur-
vivers (a), patients dying in the later course (b) and 
those dying within 1o days (c). 
cyte numbers as well. 
DISCUSSION 
Measurement of the CL response of whole blood samples 
to in vitro-stimulation seems to be a reliable assay for 
estimation of phagocytotic capacity (Ewetz et a l . 1981, 
Tono-Oka et al.1983). Use of highly diluted blood and op-
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sonized particles provides Information exclusively about 
the phacocytotic capacity of the PMN c e l l s . Facing c l i n i -
cal employment of the assay, time consuming ce l l Separa-
tion methods are no longer necessary, which may also im-
pair granulocytic function (Ogle et a l . 1985). Moreover, 
fa l s i f i c a t i o n of CL values by high erythrocyte numbers 
(quench effect) may be limited, i f highly diluted blood 
samples are used (Allen et a l . 1982, Redl et a l . 1983, 
Szczeponik 1986). 
With the assay procedure applied in this study a de-
pressing influcence of anesthesiologic-operative trauma to 
the excitability of PMN granulocytes could be clearly de-
monstrated. In this respect, longer Operation times indu-
ced also a slower increase of specific CL capacity f o l l o -
wing the primary decrease (data not shown). Nonbacterial 
inflammation as part of each wound healing el i c i t e d excit-
ability of the PMN cells corresponding to the healing 
course. 
An increased CL response of the granulocytes to 
microbial inflammation has been described recently (Bar-
bour et a l . 198o, Allen et a l . 1982, Tono-Oka et a l . 
1983). Interestingly, in our study blood samples either 
from moderate or severe inflamed patients showed an equal-
ly elevated specific CL response. This is in contrast to 
results shown by Allen et a l . 1982 and Tono-Oka et a l . 
1983. Latter authors only found an increased total exci-
t a b i l i t y during infection answer. Enhancement of total CL 
activity elicited by an exogenous Stimulus according to 
the degree of inflammation primarily reflected a rise of 
granulocyte numbers in peripheral blood and only in fatal 
sepsis a further increase of specific CL ac t i v i t y . In the 
later course of c l i n i c a l similarly severe sepsis granu-
locytes of non-survivers have been considerably more ex-
citable than those of survivors. Highest CL values we-
re observed in patients, who died very early throughout 
the septic course (Fig. 4). This Observation might sug-
gest an overshooting in defense power in the latter pa-
tients. By that means, hyperreactivity of phagocytes to 
Stimuli like microbes, c e l l debris or other foreign sub-
stances in the organism may lead locally to a tremendous 
release of toxic oxygen species as well as lysosomal en-
zymes greatly overstressing the regulatory inhibitor Po-
tential with fatal consequences (Jochum et a l . 1986). 
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ticosteroids compared, endotoxemic 
shock, 279, 283 
Early fracture stabilization (osteosynthesis), 
prevention of ARDS and MOF, 163-
167, 169 
pros and cons, listed, 167 
Edema, pulmonary. See Pulmonary edema 
Elastase, granulocyte 
corticosteroid effect, 262, 266, 270 
immunoassay quantification, 10, 11, 13, 
41-43, 45-47 
and organ failure/ARDS, 10, 11, 13, 
70-74 
Electrophoresis, SDS-PAGE, hemofiltration 
in septic acute renal failure, 242, 247 
Endotoxemic shock, 215-217, 220-221 
corticosteroid treatment, 249, 252-255, 
263, 264, 270 
fluid treatment of experimental mesen-
teric shock, 205-207 
Gram-negative septicemia, 215-217, 
220-221 
see also Corticosteroids compared, endo-
toxemic shock, rats 
Energy pathway, corticosteroid treatment of 
septic shock, 250, 254-255 
Escherichia coli, 205-207 
Ethical considerations 
naloxone, septic shock, postoperative 
symptomatic management, 
191-192 
sepsis, prediction of outcome, 29 
Extracorporeal membrane oxygenation, sep-
tic shock, postoperative, 192 
332 / Index 
Factor Xu (Hageman factor), 78, 80,83 
ß-Factor Xüa inhibition, polytraumatized pa-
tients vs. normals, plasma, 77-84 
antithrombin III, 77, 78, 82, 83 
C,-esterase inhibitor, 77, 78, 81, 83, 84, 
101 
factor XII (Hageman factor), 78, 80, 83 
kallikrein inhibition, 77, 78, 81-83 
a2-rnacroglobulin, 78, 82, 83 
mortality, 80-84 
prekallikrein, 77, 78, 80, 82, 83 
Prothrombin, 77, 83, 98 
Fat 
dietary, and lung Surfactant, multiple 
trauma, 296, 301-302 
embolism, Ventilation, prevention of 
ARDS and MOF, 168 
Fatty acids 
free, prediction of outcome, trauma/sep-
sis, 87, 88, 90 
lung Surfactant and parenteral nutrition, 
multiple trauma, 300-301 
Fibrinogen, corticosteroids compared, endo-
toxemic shock, 279, 280, 283 
Fibronectin, 210-213 
and organ failure scores, septic patients, 
68, 72, 73 
Flow, physiologic monitoring and therapy, 
high-risk surgical patients, 104 
Fluid management 
experimental mesenteric shock, 205-207 
and hemodynamics monitoring, septic 
shock, 124-126 
physiologic monitoring and therapy, high-
risk surgical patients, 106-107 
unrecognized hypovolemic shock, 106 
and Ventilation, 180 
see also Hemodilution, preoperative iso-
volemic, and subsequent infection 
Fluid replacement with colloid-containing So-
lution, advanced septic shock with 
MOF, 139-140, 143 
increased permeability and pulmonary 
edema, 142-143 
Fluid resuscitation, hydroxyethyl starch vs. 
Ringer's lactate, traumatic-hemor-
rhagic shock, 197-203 
albumin loss, 200-203 
ARDS, 197, 203 
blood pressure, 198, 199 
colloid cf. crystalloid, 197 
extravascular lung water, 198, 200, 201, 
203 
fluid loss into Peritoneum, 200-201 
pulmonary edema, 197, 203 
FMLP, 262, 264, 266, 268 
Fractures, prevention of ARDS and MOF 
early stabilization, 163-167, 169 
pros and cons, listed, 167 
and Ventilation, 168-169 
Free radicals, oxygen, 103, 216-217, 221, 
269, 270, 283; see also Lung Surfac-
tant replacement and oxygen free radi-
cal-induced respiratory failure, guinea 
pigs 
Gadolinium chloride RES blockade, acute 
septic Peritonitis and shock, rat, 
323-328 
cecal ligation and Perforation, 323-324 
liver, effects on, 327 
LPS effect, 324-326, 328 
mortality, 324-326 
splenectomy, 325-328 
Gastrointestinal tract and Hannover Intensive 
Score, 23-24 
Glasgow Coma Scale, 24, 27, 29 
early fracture stabilization, prevention of 
ARDS and MOF, 166 
Glucocorticoids in septic shock, 193, 250-
252, 255-256; see also Dexa-
methasone 
Glucose 
and corticosteroids compared, endotox-
emic shock, 275-277, 283-284 
prediction of outcome, trauma/sepsis, 87, 
88,91,92 
Glucose-insulin-potassium (GIK) in Peritoni-
tis with hypodynamic septic shock, 
315-318 
complications, 317 
after failure of volume loading and cate-
cholamines, 315, 318 
hemodynamics, 316-318 
inotropic action of insulin, 317-318 
renal failure, acute, 315 
Index / 333 
Gram-negative septicemia, pathophysiology, 
215-217, 219-221 
Granulocytes, 176, 210 
corticosteroid treatment of septic shock, 
261,262, 264-270, 283 
enzymes/proteins, quantification with im-
munoassay, 10, 41-47 
assays, 46, 47 
elastase, 10, 11, 13, 41-43, 45-47 
lactoferrin, 42, 43, 46, 47 
myeloperoxidase, 41-43, 46-47 
function, chemiluminescence studies, 
postoperative infection, 51-56 
dilution, 56 
hyperreactivity, 56 
and leukocyte numbers, 53-55 
measurement, 52 
and mortality, 52-53 
septic patients, 52-54 
survivors, 54, 55 
see also Elastase, granulocyte 
GTP metabolism, 59, 63 
Hageman factor (factor XII), 78, 80, 83 
Hannover Intensive Score, 17-21, 23-24 
listed, 23-24 
Heart 
correlation with functional impairment, 
129, 132, 135-137 
PCWP, 129, 132, 136 
left ventricular function, 129, 132, 135-
137 
septic Peritonitis, 110, 111, 113 
septic shock, postoperative, sympto-
matic therapeutic management, 
190-191 
rate, septic Peritonitis, 110-111 
Hematocrit 
fluid treatment, experimental mesenteric 
shock, 205-207 
preoperative isovolemic hemodilution, 
209-213 
Hemodilution, preoperative isovolemic, and 
subsequent infection, 209-213 
albumin, 210-212 
antithrombin III, 209-212 
colloids, 209, 210, 212, 213 
dextran, 210-213 
cf. hydroxyethyl starch, 210-213 
hematocrit, 209-213 
monocyte-phagocyte System, 209, 210, 
212 
Hemodynamics 
corticosteroid treatment of septic shock, 
250 
glucose-insulin-potassium (GIK) in Peri-
tonitis with hypodynamic septic 
shock, 316-318 
hemofiltration, septic acute renal failure, 
228, 229, 231-232, 237, 242 
Swan-Ganz monitoring, 228, 231 
inotropic support, non-adrenergic, septic 
shock, 319-320 
physiologic monitoring and therapy, high-
risk surgical patients, 103-106 
flow maldistribution vs. low flow, 104 
septic shock, postoperative, symptomatic 
therapeutic management, 186-187, 
190-191 
Hemodynamics correlated with functional 
impairment, sepsis, 129-137 
cardiac Output, 131, 135-136 
heart, 129, 132, 135-137 
left ventricular function, 129, 132, 
135-137 
PCWP, 129, 132, 136 
lactate, 133, 137 
mortality, 129, 130, 133,134 
organ failure, kidney and lung, 129, 
135-136 
oxygen 
D 0 2 - V 0 2 relationship, 129, 132-137 
transport, 136 
patient data, 130 
radial artery catheter, 131 
total peripheral resistance, 130, 133, 135 
Hemodynamics monitoring with and without 
Swan-Ganz catheter, septic shock, 
123-127 
cardiac Output, 123, 124, 126, 127 
fluid management, 124-126 
invasive monitoring, risks, 126 
PA hypertension, 124 
pulmonary artery, catheterization, 
123-124' 
pulmonary capillary wedge pressure, 123, 
124, 126, 127 
334 / Index 
renal failure, 126 
systemic vascular resistance, 123, 124, 
126, 127 
Hemofiltration, continuous, septic acute 
renal failure, 225-232, 235-238, 240 
arteriovenous, 235-238, 240-247 
BUN, 226, 227, 236 
complications (bleeding), 230, 237 
Creatinine, 226-227, 236, 245 
hemodynamics, 228, 229, 231, 232, 237, 
242 
Swan-Ganz monitoring, 228, 231 
heparin, 226, 227, 236 
lung function, 245 
extravascular lung water, 227, 228, 
232 
metabolites liberated from bloodstream, 
241-243 
HMW proteins, 241, 242, 247 
Prostaglandins, 242, 246 
SDS-PAGE, 242,247 
thromboxane, 242, 246 
MOF, 225,231,232, 237 
mortality, 231, 232, 237 
pump driven, 225-232, 236 
retrospective study, 241, 242 
sodium, potassium and phosphate, 
236-237 
see also Plasma exchange, septic shock 
Heparin and hemofiltration, 226, 227, 236 
HGH, prediction of outcome, trauma/sepsis, 
87, 88, 91 
High molecular weight proteins, hemofiltra-
tion, septic acute renal failure, 241, 
242, 247 
High-risk patients. See Monitoring, physio-
logic, and therapy, high-risk surgical 
patients 
Hydroxyethyl starch 
cf. dextran, preoperative isovolemic he-
modilution, 210-213 
fluid treatment, experimental mesenteric 
shock, 205-207 
see also Fluid resuscitation, hydroxyethyl 
starch vs. Ringer's lactate, trau-
matic-hemorrhagic shock 
Hyperreactivity of granulocytes, chemilumi-
nescence studies, postoperative infec-
tion, 56 
Hypodynamie shock. See Glucose-insulin-po-
tassium GIK) in Peritonitis with hypo-
dynamic septic shock 
Hypovolemic shock, unrecognized, physio-
logic monitoring and therapy, high-
risk surgical patients, 106; see also 
Fluid resuscitation, hydroxyethyl 
starch vs. Ringer's lactate, traumatic-
hemorrhagic shock; Scoring Systems/ 
prediction, hypovolemic and traumatic 
shock 
Igs, 210-213 
Immune System, and Hannover Intensive 
Score, 24 
Immunoassay, granulocyte enzymes/proteins 
quantification, 10, 41-47 
Immunoglobulins, 210-213 
Inflammation, corticosteroid treatment of 
septic shock, 250-251, 274 
Inhalation injury, extravascular lung water, 
major burns with sepsis, 145, 150 
Injury Severity Score, prediction of outcome, 
trauma/sepsis, 86, 90, 93, 165, 
169-171 
Inotropic action, insulin, 317-318 
Inotropic support, non-adrenergic, in septic 
shock, dog, 319-321 
amrinone, 320-321 
myocardial depression, 319-320 
adrenergic resistance, 319-320 
calcium metabolism, abnormal, 319 
Insulin. See Glucose-insulin-potassium (GIK) 
in Peritonitis with hypodynamic septic 
shock 
Inverse ratio Ventilation, 177-179 
Isovolemic hemodilution. See Hemodilution, 
preoperative isovolemic, and subse-
quent infection 
Kallikre ininhibition in septicemia, 98, 100 
and ß-factor Xlla inhibition, polytrauma-
tized patients vs. normals, 77, 78, 
81-83 
Ketanserin. See Respiratory failure, acute, 
ketanserin administration 
Ketone, blood, scoring systems/prediction, 
ARDS and MOF, 8, 13 
Kidneys 
Index / 335 
and Hannover Intensive Score, 23 
prediction of outcome, trauma/sepsis, 87-
90, 92 
see also Renal failure 
Lactate 
corticosteroids compared, endotoxemic 
shock, 275, 277, 281 
hemodynamics correlated with functional 
impairment, 133, 137 
prediction of outcome, trauma/sepsis, 
87-90 
Ringer's, fluid treatment, experimental 
mesenteric shock, 205-207; see 
also Fluid resuscitation, hydroxy-
ethyl starch vs. Ringer's lactate, 
traumatic-hemorrhagic shock 
Lactoferrin, granulocyte, immunoassay 
quantification, 42, 43, 46, 47 
Lavage, pulmonary, multiple trauma, 296, 
299-201 
Lecithin, lung Surfactant and parenteral nutri-
tion, multiple trauma, 299, 300, 302 
Leprosy, 220 
Leukocytes 
corticosteroids compared, endotoxemic 
shock, 279-283 
numbers, and granulocyte function, che-
miluminescence studies, postoper-
ative infection, 53-55 
see also Granulocytes 
Leukotrienes, corticosteroid treatment of sep-
tic shock, 253 
Lipid peroxidation, lung Surfactant replace-
ment and free radical-induced respira-
tory failure, 312 
Lipopolysaccharide, gadolinium chloride 
RES blockade, acute septic Peritonitis 
and shock, 324-326, 328 
Liver 
and acute respiratory failure, ketanserin 
administration, 158 
bilirubin, 277,278 
failure 
correlated with metabolic and lympho-
cyte parameters, septic pa-
tients, 69, 73, 75 
hypercatabolic, early predictors, sep-
sis, 118-119 
fatty, corticosteroids compared, endotox-
emic shock, 281, 284 
gadolinium chloride RES blockade, acute 
septic Peritonitis and shock, 327 
transaminases, corticosteroids compared, 
275, 277, 278, 281 
Lung 
failure, correlation with 
functional impairment, 129, 135, 136 
metabolic and lymphocyte parameters, 
septic patients, 69, 70 
and Hannover Intensive Score, 23 
hemofiltration, septic acute renal failure, 
245 
vascular resistance, septic Peritonitis, 
110, 112 
see also Methylprednisolone, high-dose 
preoperative, maintenance of pul-
monary permeability; Pulmonary 
entries; Respiratory entries; Venti-
latory management 
Lung Surfactant and parenteral nutrition, 
multiply traumatized rat, 295-302 
fat emulsion cf. carbohydrate calories, 
296, 301-302 
hypo- cf. normocaloric regimens, 
296-302 
lavage, pulmonary, 296, 299-301 
nitrogen balance, 296-297 
phospholipid composition, 295, 298-302 
DPPC, 295, 298, 299, 302 
fatty acid pattern, 300-301 
lecithin species, 299, 300, 302 
Ventilation, 295 
Lung Surfactant replacement and oxygen free 
radical-induced respiratory failure, 
guinea pigs, 305-312 
atelectasis, 310 
compliance, 306, 308, 309, 311 
lipid peroxidation, 312 
replacement Surfactant, rabbit, 306 
vs. saline, 306, 308 
SOD, 305, 309 
Superoxide radicals, 305 
and/or Ventilation, 306, 308, 312 
xanthine oxidase, 305, 309-312 
Lung water, extravascular 
and acute respiratory failure, ketanserin 
administration, 153-156 
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advanced septic shock with MOF, 
139-144 
fluid replacement with calloid-contain-
ing Solutions, 139-140, 143 
increased permeability, 142-143 
intravascular starling forces, 139, 142 
microvascular hydrostatic pressure, 
139-144 
PCWP, 139-143 
plasma colloid osmotic pressure, 
139-143 
pulmonary edema, 142-143 
fluid resuscitation, hydroxyethyl starch 
vs. Ringer's lactate, 198, 200-
201,203 
hemofiltration, septic acute renal failure, 
227, 228, 232 
major burns with sepsis, 145-151 
arterial catheter, 146 
associated microorganisms, 148, 149 
increased microvascular permeability, 
145, 150, 151 
inhalation injury, 145, 150 
microvascular hydrostatic pressure 
(Pmv), 145 
mortality, 148, 150 
PCWP, 146-151 
plasma colloid osmotic pressure 
(COP), 147-150 
and pulmonary edema, 145, 150 
Lymph, high-dose preoperative methylpred-
nisolone, maintenance of pulmonary 
permeability, sheep, 288-292 
Lysosomal enzymes, high-dose preoperative 
methylprednisolone, maintenance of 
pulmonary permeability, 287-288; see 
also Cl-esterase inhibitor; Elastase, 
granulocyte 
«2-Macroglobulin, 210-212 
and ß-factor Xlla inhibition, polytrauma-
tized patients vs. normals, 78, 82, 
83 
and organ failure scores, septic patients, 
68, 70-74 
Macrophages, D-erythro-neopterin levels, 
ICU patients with severe complica-
tions, 59, 64 
Meningococcal infection, plasma exchange, 
septic shock, 218-221 
Mesenteric shock, experimental, fluid treat-
ment, 205-207 
Methylprednisolone cf. other corticosteroids, 
septic/endotoxemic shock, 251, 253-
254, 256, 261,274-282, 284 
Methylprednisolone, high-dose preoperative, 
maintenance of pulmonary permeabil-
ity, 254, 287-292 
ARDS, 287-288 
lymph flow, 288-291 
ly sosomal enzymes, 287, 288 
platelets, 287-289, 292 
Prostaglandins, 287-288, 291-292 
and pulmonary circulation, 288 
sheep, chronic lung lymph fistula, 
289-292 
Starling equation, 288-289 
thromboxanes, 291-292 
Microvascular hydrostatic pressure (Pmv), 
extravascular lung water 
advanced septic shock with MOF, 
139-144 
major burns with sepsis, 145 
Monitoring, physiologic, and therapy, high-
risk surgical patients, 103-107 
branch chain decision tree, 106 
fluid management, aggressive, 106-107 
unrecognized hypovolemic shock, 106 
hemodynamics, 103-106 
maldistribution of flow vs. low flow, 104 
oxygen transport, 103-106 
survivors cf. nonsurvivors, 103-105 
see also Hemodynamics, monitoring with 
and without Swan-Ganz catheter, 
septic shock 
Monocytes 
activated, Gram-negative septicemia, 217, 
219, 220 
-phagocyte System, preoperative isovo-
lemic hemodilution, 209, 210, 212 
Mortality 
corticosteroids compared, endotoxemic 
shock, 282-283 
extravascular lung water, major burns 
with sepsis, 148, 150 
ß-factor Xlla inhibition, polytraumatized 
patients vs.normals, 80-84 
Index / 337 
gadolinium chloride RES blockade, acute 
septic Peritonitis and shock, 
324-326 
granulocyte function, chemiluminescence 
studies, postoperative infection, 
52-53 
hemodynamics correlated with functional-
impairment, 129, 130, 133-134 
hemofiltration, septic acute renal failure, 
231, 232, 237 
D-erythro-neopterin levels, ICU patients 
wim severe complications, 60 
and proenzyme functional inhibition in-
dex, predictor in septicemia, 99 
Multiple organ failure (MOF) 
hemofiltration, septic acute renal failure, 
225,231,232,237 
prevention, early fracture stabilization 
(osteosynthesis), 163-167, 169 
pros and cons, listed, 167 
prevention, mechanical Ventilation, 163, 
167-171 
pros and cons, 167 
see also Early fracture stabilization (os-
teosynthesis), prevention of ARDS 
and MOF; Scoring systems/pre-
diction, ARDS and MOF; under 
Lung water, extravascular 
Multiple trauma. See Trauma 
Myeloperoxidase, granulocyte, immunoassay 
quantification, 41-43, 46-47 
Myocardial depression. See Cardiac Output; 
Heart; Hemodynamics entries 
Naloxone, septic shock, postoperative symp-
tomatic therapeutic management, 191 
ethical considerations, 191-192 
D-erythro-Neopterin levels, ICU patients 
with severe complications, 59-64 
case records, 62 
GTP metabolism, 59, 63 
macrophage, 59, 64 
mortality, 60 
sepsis, 60, 62 
Statistical evaluation, 60 
survivors, 60-61 
Nitrogen 
balance, lung Surfactant and parenteral 
nutrition, multiple trauma, 
296-297 
BUN, 87-90, 92, 226, 227, 236 
excretion, early predictors, sepsis, 116, 
119 
Nonsteroidal anti-inflammatory agents, corti-
costeroid treatment cf. septic shock, 
253-254, 256 
Nonthyroidal illness (NTI), 92-93 
Osmolality, prediction of outcome, trauma/ 
sepsis, 87-90, 92 
Osteitis, early fracture stabilization (osteo-
synthesis), prevention of ARDS and 
MOF, 166 
Osteosynthesis, early, prevention of ARDS 
and MOF, 163-167, 169 
pros and cons, listed, 167 
Oxygen 
administration, 177-178 
consumption, early predictors, sepsis, 
116-119 
hemodynamics correlated with functional 
impairment 
D 0 2 - V 0 2 relationship, 129, 132-137 
transport, 136 
radicals, 163, 216-217, 221, 269, 270, 
283; see also Lung Surfactant re-
placement and oxygen free radical-
induced respiratory failure, guinea 
Pigs 
transport 
physiologic monitoring and therapy, 
high-risk surgical patients, 
103-106 
septic shock, postoperative, sympto-
matic therapeutic management, 
189, 190 
Oxygenation, extracorporeal membrane, 
postoperative septic shock, 192 
Parenteral nutrition, postoperative septic 
shock, 189, 191; see also Lung Sur-
factant and parenteral nutrition, multi-
ply traumatized rat 
PCWP. See Pulmonary capillary wedge pres-
sure (PCWP) 
PEEP 
plasma exchange, septic shock, 218 
septic shock, postoperative, symptomatic 
therapeutic management, 190-192 
338 / Index 
Perfluorochemicals, fluid treatment, experi-
mental mesenteric shock, 205-207 
Peritoneum, fluid loss into, fluid resuscita-
tion, hydroxyethyl starch vs. Ringer's 
lactate, 200-201 
Peritonitis, postoperative, symptomatic thera-
peutic management, 187, 188; see also 
Gadolinium chloride RES blockade, 
acute septic Peritonitis and shock, rat; 
Glucose-insulin-potassium (GIK) in 
Peritonitis with hypodynamic septic 
shock 
Peritonitis, septic, hemodynamic patterns, 
109-114 
heart rate, 110-111 
physiologic measurements, 110-111 
cardiac Output, 110, 111, 113 
left ventricular stroke work, 110, 111, 
113 
mean arterial pressure, 110, 111 
pulmonary vascular resistance, 110, 
112 
total peripheral resistance, 110-112 
Swan-Ganz catheter, 109-110 
Permeability, microvascular 
and acute respiratory failure, ketanserin 
administration, 157, 158 
corticosteroid treatment of septic shock, 
254 
and extravascular lung water 
advanced septic shock, 142-143 
major burns with sepsis, 145, 150, 
151 
see also Methylprednisolone, high-dose 
preoperative, maintenance of pul-
monary permeability 
Phagocytes, preoperative isovolemic hemodi-
lution, 209, 210, 212 
Phosphate, hemofiltration, septic acute renal 
failure, 236-237 
Phospholipids, lung Surfactant and parenteral 
nutrition, multiple trauma, 295, 
298-302 
Physiologic monitoring. See Monitoring, 
physiologic, and therapy, high-risk 
surgical patients 
Plasma colloid osmotic pressure and extra-
vascular lung water 
advanced septic shock with MOF, 
139-143 
major burns with sepsis, 147-150 
Plasma exchange, septic shock, 215-221 
antithrombin III, 218, 219 
ARDS, 217 
meningococcal infection, 218-221 
pathophysiology, Gram-negative septi-
cemia, 215-217 
activated monocytes, 217, 219, 220 
complement activation, 216, 217, 
219-221 
endotoxin, 215-217, 220, 221 
PEEP, 218 
see also Hemofiltration, continuous, sep-
tic acute renal failure 
Plasminogen, proenzyme functional inhibi-
tion index, predictor in septicemia, 
77, 83, 98, 100 
Platelets 
corticosteroids compared, endotoxemic 
shock, 279, 283 
methylprednisolone, high-dose preopera-
tive, maintenance of pulmonary 
permeability, 287-289, 292 
PMNs. See Granulocytes 
Polytrauma. See Trauma 
Positive end expiratory pressure (PEEP), 
178, 179, 190-192 
Postoperative metabolic and lymphocyte pa-
rameters, scoring systems/prediction, 
72, 74; see also Septic shock, postop-
erative, symptomatic therapeutic man-
agement; under Granulocytes 
Potassium, hemofiltration, septic acute renal 
failure, 236-237; see also Glucose-in-
sulin-potassium (GIK) in Peritonitis 
with hypodynamic septic shock 
Prealbumin and organ failure scores, septic 
patients, 68, 70-74 
Prediction. See Scoring systems/prediction 
entries 
Prednisolone 
corticosteroids compared, endotoxemic 
shock, 274-282, 284 
treatment of septic shock, 261-267, 269 
Prekallikrein 
Index / 339 
and ß-factor Xlla inhibition, polytrauma-
tized patients vs. normals, 77, 78, 
80, 82, 83 
and organ failure scores, septic patients, 
70-75 
and proenzyme functional inhibition in-
dex, predictor in septicemia, 98, 
100 
Preoperative treatments. See Hemodilution, 
preoperative isovolemic, and subse-
quent infection; Methylprednisolone, 
high-dose preoperative, maintenance 
of pulmonary permeability 
Proenzyme functional inhibition index, pre-
dictor in septicemia, 77, 97-101 
abdominal surgery, 99-100 
antiplasmin, 77, 83, 98, 100 
antithrombin HI, 98, 100, 101 
chromogenic peptide Substrate, 99 
functional protease inhibitor deficiencies, 
100, 101 
kallikrein inhibition, 98, 100 
and mortality, 99 
multiple trauma, 99 
Plasminogen, 77, 83, 98, 100 
prekallikrein, 98, 100 
Prothrombin, 77, 83, 98, 100 
Prognostic indices. See Scoring systems/pre-
diction entries 
Prostaglandins, 217 
corticosteroid treatment of septic shock, 
253 
hemofiltration, septic acute renal failure, 
242, 246 
methylprednisolone, high-dose preopera-
tive, 287-288, 291-292 
scoring systems/prediction, ARDS and 
MOF, 9 
see also Arachidonic acid cascade 
Protease inhibitor deficiencies, functional, 
predictor in septicemia, 100, 101 
a,-Proteinase inhibitor, 210-212 
Prothrombin, 77, 83, 98, 100 
Pseudomonas, 253 
aeruginosa, 216 
Pulmonary artery 
catheterization, and hemodynamics moni-
toring, septic shock, 123-124; see 
also Catheters, arterial 
hypertension, and hemodynamics moni-
toring, septic shock, 124 
pressure, mean, and acute respiratory 
failure, ketanserin administration, 
153-158 
Pulmonary capillary wedge pressure (PCWP) 
correlation with functional impairment, 
129, 132, 136 
extravascular lung water 
advanced septic shock with MOF, 
139-143 
major burns with sepsis, 146-151 
and hemodynamics monitoring, septic 
shock, 123-124, 126-127 
septic shock, postoperative, symptomatic 
therapeutic management, 190 
Pulmonary edema 
cf. ARDS, scoring, 3-4 
extravascular lung water 
advanced septic shock with MOF, 
142-143 
major burns with sepsis, 145, 150 
fluid resuscitation, hydroxyethyl starch 
vs. Ringer's lactate, 197, 203 
septic shock, postoperative, symptomatic 
therapeutic management, 190 
and Ventilation, 175-176 
functional residual capacity, 176, 178, 
181 
Radial artery catheter, correlation with func-
tional impairment, 131 
Renal failure 
correlation with 
functional impairment, 129, 135, 136 
metabolic and lymphocyte parameters, 
septic patients, 69-74 
glucose-insulin-potassium (GIK) in Peri-
tonitis with hypodynamic septic 
shock, 315 
and hemodynamics monitoring, septic 
shock, 126 
and Ventilation, 180 
see also Hemofiltration, continuous, sep-
tic acute renal failure 
Resistance. See Vascular resistance 
Respiratory failure, acute, ketanserin admin-
istration, 153-158 
340 / Index 
extravascular lung water, 153-156 
liver function, 158 
mean pulmonary artery pressure, 
153-158 
permeability, microvascular, 157, 158 
Serotonin, 153, 157-158 
Swan-Ganz catheter, 154 
see also Lung Surfactant replacement and 
oxygen free radical-induced respi-
ratory failure, guinea pigs 
Respiratory System, and Hannover Intensive 
Score, 23 
Reticuloendothelial System, 207, 210, 212-
213, 249, 283; see also Gadolinium 
chloride RES blockade, acute septic 
Peritonitis and shock, rat 
Retinol-binding protein and organ failure 
scores, septic patients, 68, 72 
Ringer's lactate, fluid treatment, experimen-
tal mesenteric shock, 205-207; see 
also Fluid resuscitation, hydroxyethyl 
starch vs. Ringer's lactate, traumatic-
hemorrhagic shock 
Saline cf. lung Surfactant replacement, free 
radical-induced respiratory failure, 
306, 308 
Schwartzman reaction, 215 
Scoring systems/prediction. See also D-ery-
thro-Neopterin levels, ICU patients 
with severe complications; Proenzyme 
functional inhibition index, predictor 
in septicemia 
Scoring systems/prediction, ARDS and 
MOF, 3-13 
clinical parameters, 7-8 
granulocyte enzymes and proteins, immu-
noassay quantification, 10, 41-47 
elastase, 10, 11, 13 ,41^3 ,45-47 
laboratory parameters, 8-12 
arachidonic acid cascade, 9, 13, 59, 
176 
blood ketone ratio, 8, 13 
central plasma clearance rate of amino 
acids, 8, 13 
complement, 9-10, 12, 13, 59 
MOF, in sepsis, 4-6 
listed, 5 
predisposing conditions, at-risk patients, 
6-7 
true ARDS cf. other pulmonary edema, 
3-4 
Scoring systems/prediction, hypovolemic and 
traumatic shock, 17-21, 23-24 
APACHE, 17-21,26-29 
Glasgow Coma Scale, 24, 27, 29, 166 
Hannover Intensive Score (HIS), multiple 
organ Systems, 17-21, 23-24 
listed, 23-24 
Injury Severity Score (ISS), 86, 90, 93, 
165, 169-171 
TISS, 17-21 
trauma score, 17 
Scoring systems/prediction, sepsis and 
trauma, 25-29, 67-75, 85-93 
amino acids, 67, 70-73 
antithrombin III, 70-75 
a,-antitrypsin, 68, 70-74 
BUN, 87-90, 92 
case records, 68 
Cl-esterase inhibitor, 70-72 
circulatory, 69-71, 73 
cortisol, 87, 88, 91, 92 
C-peptide, 87-89, 91,92 
C-reactive protein, 68, 70-74 
early, 155-119 
cardiac Output, 117, 118 
C0 2 , 118, 119 
liver failure, hypercatabolic, 118-119 
nitrogen excretion, 116, 119 
oxygen consumption, 116-119 
statistics, 116 
total peripheral resistance, 116-119 
elastase, 70-74 
ethical considerations, 29 
fibronectin, 68, 72, 73 
free fatty acids, 87-88, 90 
glucose, 87-88, 91, 92 
HGH, 87, 88, 91 
kidney, 69-71, 73, 74, 87, 90, 92 
lactate, 87-90 
liver, 69, 73, 75 
lung, 69, 70 
a2-macroglobulin, 68, 70, 71-74 
cf. normals and postoperative nonseptic, 
72,74 
Index / 341 
osmolality, 87, 88, 90, 92 
prealbumin, 68, 70-74 
prekallikrein, 70-75 
prognostic indices, 33-39 
graphs of scores, 35 
listed, 35 
statistically significant problems, 34-
36, 39 
reference frame, 28-29 
retinol-binding protein, 68, 72 
spontaneous blastogenesis, 70, 72, 74 
statistics, 70 
T cells 
helper and suppressor, 70-72 
subset ratio, 70-74 
thyroid hormones in nonthyroidal illness, 
87, 89-93 
transferrin, 68, 70-75 
transition scales, 25-26 
Sepsis 
granulocyte function, chemiluminescence 
studies, postoperative infection, 
52-54 
major burns with, extravascular lung 
water, 145-151 
MOF in, 4-6 
D-erythro-neopterin levels, ICU patients 
with severe complications, 60, 62 
see also Hemodynamics correlated with 
functional impairment, sepsis; 
Hemofiltration, continuous, septic 
acute renal failure; Scoring sys-
tems/prediction, sepsis and trauma 
Septicemia. See Proenzyme functional inhibi-
tion index, predictor in septicemia 
Septic shock, postoperative, symptomatic 
therapeutic management, 185-193 
antibiotics, 188, 189 
arachidonic acid cascade, blocking, 192 
catecholamines, exogenous, 189, 191 
glucocorticoids, 193 
hemodynamics, 186-187 
left ventricular function, 190-191 
Swan-Ganz catheter, PCWP, 190 
naloxone, 191 
ethical considerations, 191-192 
parenteral nutrition, 189, 191 
Peritonitis, 187, 188 
selective decontamination of digestive 
tract, 188 
respiratory, 187, 191 
ARDS, 187, 191-192 
edema, 190 
extracorporeal membrane oxygena-
tion, 192 
oxygen transport, 189, 190 
volume therapy (colloid), 189, 190 
see also Corticosteroids in treatment of 
septic shock; Gadolinium chloride 
RES blockade, acute septic Peri-
tonitis and shock; Glucose-insulin-
potassium (GIK) in Peritonitis with 
hypodynamic septic shock; Hemo-
dynamics, monitoring with and 
without Swan-Ganz catheter, sep-
tic shock; Inotropic support, non-
adrenergic, in septic shock, dog; 
Plasma exchange, septic shock; 
under Lung water, extravascular 
Serotonin, 217 
and acute respiratory failure, ketanserin 
administration, 153, 157, 158 
Sodium, hemofiltration, septic acute renal 
failure, 236-237 
Splenectomy, gadolinium chloride RES 
blockade, acute septic Peritonitis and 
shock, rat, 325-328 
Starling equation/forces, 139, 142, 288-289 
Superoxide dismutase, lung Surfactant re-
placement and free radical-induced 
respiratory failure, 305, 309 
Superoxide radicals, lung Surfactant replace-
ment and free radical-induced respira-
tory failure, 305 
Surfactant. See Lung Surfactant entries 
Survival 
corticosteroid treatment of septic shock, 
255-257 
granulocyte function, chemiluminescence 
studies, postoperative infection, 
54-55 
D-erythro-neopterin levels, ICU patients 
wim severe complications, 60, 61 
physiologic monitoring and therapy, high-
risk surgical patients, 103-105 
Swan-Ganz catheter 
342 /Index 
and acute respiratory failure, ketanserin 
administration, 154 
hemofiltration, septic acute renal failure, 
228, 231 
septic Peritonitis, 109-110 
septic shock, postoperative, symptomatic 
therapeutic management, 190 
see also Catheters, arterial; Hemody-
namics, monitoring with and with-
out Swan-Ganz catheter, septic 
shock 
TBG, 87, 89, 90, 93 
T cells, 59, 63 
parameters correlated with organ failure 
scores, septic patients 
helper and suppressor, 70-72 
subset ratio, 70-74 
Thromboplastin, 217, 219, 220 
Thromboxanes 
corticosteroid treatment of septic shock, 
253 
hemofiltration, septic acute renal failure, 
242, 246 
methylprednisolone, high-dose preopera-
tive, maintenance of pulmonary 
permeability, 291-292 
scoring systems/prediction, ARDS and 
MOF, 9 
see also Arachidonic acid cascade 
Thyroid hormones 
in nonthyroidal illness (NTI), 87, 89, 
90-93 
prediction of outcome, trauma/sepsis, 87, 
89-93 
Thyroxine (T4), 87, 89-91, 93 
TISS, 17-21 
Transaminases, liver, corticosteroids com-
pared, endotoxemic shock, 275, 277, 
278, 281 
Transferrin and organ failure scores, septic 
patients, 68, 70-75 
Transition scales, 25-26 
Trauma 
multiple, proenzyme functional inhibition 
index, predictor in septicemia, 99 
score, 17 
see also ß-Factor Xlla inhibition, poly-
traumatized patients vs. normals, 
plasma; Fluid resuscitation, hy-
droxyethyl starch vs. Ringer's lac-
tate, traumatic-hemorrhagic shock; 
Lung Surfactant and parenteral nu-
trition, multiply traumatized rat; 
Scoring systems/prediction, hypo-
volemic and traumatic shock; 
Scoring systems/prediction, sepsis 
and trauma 
Triiodothyronine (T3), 87-91, 93 
TSH, 87, 89, 91-93 
Vascular resistance 
peripheral, 130, 133, 135 
early predictors, sepsis, 116-119 
septic Peritonitis, 110-112 
pulmonary, septic Peritonitis, 110, 112 
systemic, and hemodynamics monitoring, 
septic shock, 123-124, 126-127 
Ventilatory management, 175-182 
CPAP, 177, 178, 181 
CPPV, 177, 178, 181 
fluid management, 180 
IRV, 177-179 
lung Surfactant 
and parenteral nutrition, multiple 
trauma, 295 
replacement and free radical-induced 
respiratory failure, 306, 308, 
312 
oxygen administration, 177-178 
PEEP, 178, 179 
prevention of ARDS and MOF, 163, 167-
171, 182 
pros and cons, 167 
Prophylaxis cf. early therapy, 175 
pulmonary edema, 175-176 
functional residual capacity, 176, 178, 
181 
renal failure, 180 
schedule, 180-181 
Volume loading, failure, glucose-insulin-po-
tassium (GIK) following, 315, 318 
Water, extravascular lung. See Lung water, 
extravascular 
Waterhouse-Friderichsen Syndrome, 216 
Xanthine oxidase, lung Surfactant replace-
ment and free radical-induced respira-
tory failure, 305, 308-312 
ZAP, 264, 265 
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